Spectrum Pharma Climbs as FDA to Fast-Track Cancer Drug Review

Spectrum Pharmaceuticals  (SPPI), which focuses on cancer drugs, jumped on Thursday after it said the Food and Drug Administration approved fast-track status for one of its treatments.